Skip to main content
Log in

Pharmacokinetic studies in volunteers of intravenous and oral cis (Z)-flupentixol and intramuscular cis (Z)-flupentixol decanoate in viscoleo®

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

Serum concentrations of cis (Z)-flupentixol have been estimated in three male human volunteers who received cis (Z)-flupentixol by intravenous infusion, flupentixol (cis (Z)/trans (E) mixture, 1:1) orally as single and repeated doses, and i. m. cis (Z)-flupentixol decanoate in Viscoleo®. The intravenous data show that cis (Z)-flupentixol followed a multicompartment model, but it was not possible to fit the data to a two or three compartment model. The concentration curves after oral administration indicated relatively slow absorption with a peak concentration at 3–6 h, except for one case with peak at 1 h. The variation in the dosage interval after one daily oral administration was relatively limited (1.7–3.0 times), which indicates that 24 h is a reasonable dosage interval. Biological half-lives were estimated in different ways and showed some intra-individual variation; the half-life was of medium length (19–39 h). The serum concentrations after intramuscular injection of cis (Z)-flupentixol decanoate clearly demonstrated a depot effect, with a maximal concentration at 3–5 days after injection. The descending part of the serum curves allowed an approximate estimation of half-life of 3–8 days. This was not the elimination half-life, but in all probability the half-life of release of drug from the oil depot which was the rate-limiting step. From the areas under the serum concentration curves the fraction of orally administered cis (Z)-flupentixol available to the organism was calculated to be 55% (range 48–60%). The loss of drug might have been due to imcomplete absorption, but it is more likely that cis (Z)-flupentixol underwent first-pass metabolism in the gut wall and the liver. As the tablets contained about 50% cis (Z)-flupentixol, while the depot preparation contained 74% cis (Z)-flupentixol, the pharmacokinetically equivalent doses are: 10 mg tablet daily corresponds to 25 mg depot weekly. Calculation of systemic clearance gave values of 0.44–0.49 l/min, and an apparent volume of distribution was 12.5–17.2 l/kg.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Curry SH, Whelpton R, De Schepper PJ, Vranckx S, Schiff AA (1978) Plasma fluphenazine concentrations after injection of long-acting esters. Lancet 2: 1217–1218

    Google Scholar 

  • Curry SH, Whelpton R, De Schepper PJ, Vranckx S, Schiff AA (1979) Kinetics of Fluphenazine after Fluphenazine Dihydrochloride, Enanthate and Decanoate Administration to Man. Br J Clin Pharmacol 7: 325–331

    Google Scholar 

  • Johnstone EC, Crow TJ, Frith CD, Carney MWP, Price JS (1978) Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet 1: 848–851

    Google Scholar 

  • Jørgensen A, Hansen V, Dahl Larsen U, Rauf Khan A (1969) Metabolism, Distribution and Excretion of Flupentixol. Acta Pharmacol Toxicol 27: 301–313

    Google Scholar 

  • Jørgensen A, Fredricson Overø K, Hansen V (1971) Metabolism, Distribution and Excretion of Flupentixol Decanoate in Dogs and Rats. Acta Pharmacol Toxicol 29: 339–358

    Google Scholar 

  • Jørgensen A, Gottfries CG (1972) Pharmacokinetic Studies on Flupentixol and Flupentixol Decanoate in Man using Tritium Labelled Compounds. Psychopharmacologia 27: 1–10

    Google Scholar 

  • Jørgensen A, Hansen V (1976) Pharmacokinetics of Amitriptyline Infused Intravenously in Man. Eur J Clin Pharmacol 10: 337–341

    Google Scholar 

  • Jørgensen A (1978) A sensitive and specific radioimmunoassay for cis (Z)-flupentixol in human serum. Life Sci 23: 1533–1542

    Google Scholar 

  • Jørgensen A, Fredricson Overø K (1980) Clopenthixol and flupentixol depot preparations in outpatient schizophrenics. III Serum levels. Acta Psychiatr Scand 61: Suppl 279, 41–54

    Google Scholar 

  • Muusze RG, Visser-Van der Weel AJ, Van der, Verzijden R, Oei TT (1977) Fluorimetrische bepaling op de dunne laag van de blodkoncentratie van thioxanthenen (Sordinol® en Fluanxol®) na orale en intramusculaire (depot) toediening. Bulletin van de coördinatiecommissie biochemisch onderzoek van de psychiatrische instituten van de nationale ziekenhuisraad 10: 1–8

    Google Scholar 

  • Møller Nielsen I, Pedersen V, Nymark M, Franck KF, Boeck V, Fjalland B, Christensen AV (1973) The Comparative Pharmacology of Flupentixol and some Reference Neuroleptics. Acta Pharmacol Toxicol 33: 353–362

    Google Scholar 

  • Stauning JA, Kirk L, Jørgensen A (1979) Comparison of Serum Levels After Intramuscular Injections of 2% and 10% Cis (Z)-flupentixol Decanoate in Viscoleo® to Schizophrenic Patients. Psychopharmacology 65: 69–72

    Google Scholar 

  • Wiles DH, Gelder MG (1979) Plasma Fluphenazine Levels by Radioimmunoassay in Schizophrenic Patients Treated with Depot Injections of Fluphenazine Decanoate. Br J Clin Pharmacol 8: 565–570

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jørgensen, A. Pharmacokinetic studies in volunteers of intravenous and oral cis (Z)-flupentixol and intramuscular cis (Z)-flupentixol decanoate in viscoleo® . Eur J Clin Pharmacol 18, 355–360 (1980). https://doi.org/10.1007/BF00561395

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00561395

Key words

Navigation